Literature DB >> 6272569

Clinical aspects of glucagon-producing islet cell tumors.

R A Prinz, T R Dorsch, A M Lawrence.   

Abstract

Review of the 55 reported cases of glucagon-producing tumors reveals that a distinctive clinical syndrome consisting of diabetes, a peculiar dermatitis termed necrolytic migratory erythema, weight loss and an increased tendency for thrombosis is associated with these neoplasms. Normochromic normocytic anemia, hypocholesterolemia, hypoproteinemia and generalized hypoaminoacidemia are frequent laboratory findings. Definitive diagnosis of a glucagonoma requires elevation of the fasting serum glucagon level. Selective arteriography of the pancreas has been the best method for localizing these neoplasms preoperatively, but the noninvasive technics of ultrasound and CAT scanning can also be helpful. When the tumor is benign, complete surgical excision can completely reverse all the clinical manifestations of the glucagonoma syndrome and result in lasting cure. Since, however, approximately three-fourths of these tumors are malignant, palliative therapy is frequently required. Cytoreductive surgery can decrease the amount of hormone-producing tissue and can improve or even temporarily reverse the clinical symptomatology. For disseminated disease, chemotherapy is necessary. The best results have been obtained with DTIC although streptozotocin has also been used.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272569

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Retrobulbar neuritis as the first sign of the glucagonoma syndrome.

Authors:  E R Lambrecht; T L van der Loos; A H van der Eerden
Journal:  Int Ophthalmol       Date:  1987-10       Impact factor: 2.031

2.  Gastroenteropancreatic endocrine tumors.

Authors:  C Weil
Journal:  Klin Wochenschr       Date:  1985-05-15

Review 3.  Pancreatic endocrine neoplasms: a current update on genetics and imaging.

Authors:  S Philips; S N Shah; R Vikram; S Verma; A K P Shanbhogue; S R Prasad
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

4.  Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Shuren Li; Bettina Ibi; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-21       Impact factor: 9.236

Review 5.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.